Angiogenesis inhibitors in a murine neuroblastoma model: Quantitative assessment of intratumoral blood flow with contrast-enhanced gray-scale US

M. Beth McCarville, Christian J. Streck, Paxton V. Dickson, Chin-Shang Li, Amit C. Nathwani, Andrew M. Davidoff

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Purpose: To quantify intratumoral ultrasonographic (US) contrast agent flow at gray-scale imaging as a measure of functional tumor vascularity in an orthotopic murine neuroblastoma model treated with angiogenesis inhibitors. Materials and Methods: After Institutional Animal Care and Use Committee approval, retroperitoneal neuroblastomas were established in mice with unmodified NXS2 cells (n = 13) or with cells engineered to overexpress an angiogenesis inhibitor-either tissue inhibitor of matrix metalloproteinase-3 (n = 22) or a truncated soluble form of the vascular endothelial growth factor receptor-2 (truncated soluble fetal liver kinase-1; n = 13). When tumors were approximately 600 mm3, contrast material-enhanced gray-scale US was performed, and the imaging was recorded on cine clips. Regions of interest within tumors were analyzed off-line to determine postcontrast change in signal intensity (SI) from baseline to initial peak (ΔSI), rate of SI increase from baseline to initial peak (RSI), and contrast material washout. The Mann-Whitney test was used to evaluate potential differences in these US parameters between treatment groups. The mean intratumoral endothelial cell (CD34) and pericyte (smooth muscle actin [SMA]) counts at immunohistochemical analysis were also evaluated. Spearman correlation test was used to investigate the relation between US parameters and these histologic markers. Results: The ΔSI and RSI were lower in tumors overexpressing an angiogenesis inhibitor than in control tumors (all P < .03). Contrast material washout did not differ between groups. For the entire cohort, the RSI correlated with the immunohistochemical assessment of tumor vascularity (SMA and CD34 counts) (P < .003). Conclusion: Quantification of intratumoral flow of a US contrast agent at gray-scale imaging shows promise for monitoring tumor vascular response to antiangiogenic therapy.

Original languageEnglish (US)
Pages (from-to)73-81
Number of pages9
JournalRadiology
Volume240
Issue number1
DOIs
StatePublished - Jul 2006
Externally publishedYes

Fingerprint

Angiogenesis Inhibitors
Neuroblastoma
Contrast Media
Vascular Endothelial Growth Factor Receptor-2
Neoplasms
Actins
Animal Care Committees
Tissue Inhibitor of Metalloproteinase-3
Smooth Muscle Tumor
Matrix Metalloproteinase 3
Pericytes
Surgical Instruments
Smooth Muscle
Blood Vessels
Endothelial Cells

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Angiogenesis inhibitors in a murine neuroblastoma model : Quantitative assessment of intratumoral blood flow with contrast-enhanced gray-scale US. / McCarville, M. Beth; Streck, Christian J.; Dickson, Paxton V.; Li, Chin-Shang; Nathwani, Amit C.; Davidoff, Andrew M.

In: Radiology, Vol. 240, No. 1, 07.2006, p. 73-81.

Research output: Contribution to journalArticle

McCarville, M. Beth ; Streck, Christian J. ; Dickson, Paxton V. ; Li, Chin-Shang ; Nathwani, Amit C. ; Davidoff, Andrew M. / Angiogenesis inhibitors in a murine neuroblastoma model : Quantitative assessment of intratumoral blood flow with contrast-enhanced gray-scale US. In: Radiology. 2006 ; Vol. 240, No. 1. pp. 73-81.
@article{9a0ec38035234d48bfbcb56b96916ab3,
title = "Angiogenesis inhibitors in a murine neuroblastoma model: Quantitative assessment of intratumoral blood flow with contrast-enhanced gray-scale US",
abstract = "Purpose: To quantify intratumoral ultrasonographic (US) contrast agent flow at gray-scale imaging as a measure of functional tumor vascularity in an orthotopic murine neuroblastoma model treated with angiogenesis inhibitors. Materials and Methods: After Institutional Animal Care and Use Committee approval, retroperitoneal neuroblastomas were established in mice with unmodified NXS2 cells (n = 13) or with cells engineered to overexpress an angiogenesis inhibitor-either tissue inhibitor of matrix metalloproteinase-3 (n = 22) or a truncated soluble form of the vascular endothelial growth factor receptor-2 (truncated soluble fetal liver kinase-1; n = 13). When tumors were approximately 600 mm3, contrast material-enhanced gray-scale US was performed, and the imaging was recorded on cine clips. Regions of interest within tumors were analyzed off-line to determine postcontrast change in signal intensity (SI) from baseline to initial peak (ΔSI), rate of SI increase from baseline to initial peak (RSI), and contrast material washout. The Mann-Whitney test was used to evaluate potential differences in these US parameters between treatment groups. The mean intratumoral endothelial cell (CD34) and pericyte (smooth muscle actin [SMA]) counts at immunohistochemical analysis were also evaluated. Spearman correlation test was used to investigate the relation between US parameters and these histologic markers. Results: The ΔSI and RSI were lower in tumors overexpressing an angiogenesis inhibitor than in control tumors (all P < .03). Contrast material washout did not differ between groups. For the entire cohort, the RSI correlated with the immunohistochemical assessment of tumor vascularity (SMA and CD34 counts) (P < .003). Conclusion: Quantification of intratumoral flow of a US contrast agent at gray-scale imaging shows promise for monitoring tumor vascular response to antiangiogenic therapy.",
author = "McCarville, {M. Beth} and Streck, {Christian J.} and Dickson, {Paxton V.} and Chin-Shang Li and Nathwani, {Amit C.} and Davidoff, {Andrew M.}",
year = "2006",
month = "7",
doi = "10.1148/radiol.2401050709",
language = "English (US)",
volume = "240",
pages = "73--81",
journal = "Radiology",
issn = "0033-8419",
publisher = "Radiological Society of North America Inc.",
number = "1",

}

TY - JOUR

T1 - Angiogenesis inhibitors in a murine neuroblastoma model

T2 - Quantitative assessment of intratumoral blood flow with contrast-enhanced gray-scale US

AU - McCarville, M. Beth

AU - Streck, Christian J.

AU - Dickson, Paxton V.

AU - Li, Chin-Shang

AU - Nathwani, Amit C.

AU - Davidoff, Andrew M.

PY - 2006/7

Y1 - 2006/7

N2 - Purpose: To quantify intratumoral ultrasonographic (US) contrast agent flow at gray-scale imaging as a measure of functional tumor vascularity in an orthotopic murine neuroblastoma model treated with angiogenesis inhibitors. Materials and Methods: After Institutional Animal Care and Use Committee approval, retroperitoneal neuroblastomas were established in mice with unmodified NXS2 cells (n = 13) or with cells engineered to overexpress an angiogenesis inhibitor-either tissue inhibitor of matrix metalloproteinase-3 (n = 22) or a truncated soluble form of the vascular endothelial growth factor receptor-2 (truncated soluble fetal liver kinase-1; n = 13). When tumors were approximately 600 mm3, contrast material-enhanced gray-scale US was performed, and the imaging was recorded on cine clips. Regions of interest within tumors were analyzed off-line to determine postcontrast change in signal intensity (SI) from baseline to initial peak (ΔSI), rate of SI increase from baseline to initial peak (RSI), and contrast material washout. The Mann-Whitney test was used to evaluate potential differences in these US parameters between treatment groups. The mean intratumoral endothelial cell (CD34) and pericyte (smooth muscle actin [SMA]) counts at immunohistochemical analysis were also evaluated. Spearman correlation test was used to investigate the relation between US parameters and these histologic markers. Results: The ΔSI and RSI were lower in tumors overexpressing an angiogenesis inhibitor than in control tumors (all P < .03). Contrast material washout did not differ between groups. For the entire cohort, the RSI correlated with the immunohistochemical assessment of tumor vascularity (SMA and CD34 counts) (P < .003). Conclusion: Quantification of intratumoral flow of a US contrast agent at gray-scale imaging shows promise for monitoring tumor vascular response to antiangiogenic therapy.

AB - Purpose: To quantify intratumoral ultrasonographic (US) contrast agent flow at gray-scale imaging as a measure of functional tumor vascularity in an orthotopic murine neuroblastoma model treated with angiogenesis inhibitors. Materials and Methods: After Institutional Animal Care and Use Committee approval, retroperitoneal neuroblastomas were established in mice with unmodified NXS2 cells (n = 13) or with cells engineered to overexpress an angiogenesis inhibitor-either tissue inhibitor of matrix metalloproteinase-3 (n = 22) or a truncated soluble form of the vascular endothelial growth factor receptor-2 (truncated soluble fetal liver kinase-1; n = 13). When tumors were approximately 600 mm3, contrast material-enhanced gray-scale US was performed, and the imaging was recorded on cine clips. Regions of interest within tumors were analyzed off-line to determine postcontrast change in signal intensity (SI) from baseline to initial peak (ΔSI), rate of SI increase from baseline to initial peak (RSI), and contrast material washout. The Mann-Whitney test was used to evaluate potential differences in these US parameters between treatment groups. The mean intratumoral endothelial cell (CD34) and pericyte (smooth muscle actin [SMA]) counts at immunohistochemical analysis were also evaluated. Spearman correlation test was used to investigate the relation between US parameters and these histologic markers. Results: The ΔSI and RSI were lower in tumors overexpressing an angiogenesis inhibitor than in control tumors (all P < .03). Contrast material washout did not differ between groups. For the entire cohort, the RSI correlated with the immunohistochemical assessment of tumor vascularity (SMA and CD34 counts) (P < .003). Conclusion: Quantification of intratumoral flow of a US contrast agent at gray-scale imaging shows promise for monitoring tumor vascular response to antiangiogenic therapy.

UR - http://www.scopus.com/inward/record.url?scp=33745162541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745162541&partnerID=8YFLogxK

U2 - 10.1148/radiol.2401050709

DO - 10.1148/radiol.2401050709

M3 - Article

C2 - 16793972

AN - SCOPUS:33745162541

VL - 240

SP - 73

EP - 81

JO - Radiology

JF - Radiology

SN - 0033-8419

IS - 1

ER -